While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...

The FDA approved epcoritamab-bysp in combination with lenalidomide and rituximab for patients with relapsed or refractory ...

Current NCCN Guidelines recommend molecular testing for patients with follicular lymphoma, which has improved diagnostic ...

The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with ...

Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that ...

Approved and investigational agents have improved outcomes for patients with follicular lymphoma; however a growing understanding of the origins and progression of the disease might offer further ...

Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

Epcoritamab, rituximab, and lenalidomide combination is approved for relapsed/refractory follicular lymphoma, marking a first in bispecific antibody second-line treatments. The EPCORE FL-1 study ...

The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents ...

Greater follicular lymphoma risk correlated with the highest polygenic risk score, which was comprised of 5 single nucleotide polymorphisms. A subgroup of non-Hispanic white women had the highest ...